Skip to main content

Boehringer Ingelheim, Cenix in RNAi Research Deal

NEW YORK (GenomeWeb News) — Cenix BioScience will support Boehringer Ingelheim with RNAi-focused contract research services for its therapeutic drug programs under a new agreement, Cenix said today.

Cenix will apply its knowledge combining high throughput applications of RNAi-based gene silencing with phenotypic analysis in what will be a genome-scale screen using cultured human cells. Cenix will use microscopy-based assays it developed to complement proprietary assays developed by Boehringer Ingelheim to generate information about the cellular functions and loss-of-function phenotypes of analyzed genes.

Financial terms of the agreement were not released.

The Scan

UK Funds to Stay Ahead of Variants

The UK has announced a further £29.3 million to stay on top of SARS-CoV-2 variants, the Guardian reports.

Push for Access

In a letter, researchers in India seek easier access to COVID-19 data, Science reports.

Not as Cold

Late-stage trial results are expected soon for an RNA-based vaccine that could help meet global demand as it does not require very cold storage, the New York Times writes.

Genome Research Papers on Microbes' Effects on Host Transfer RNA, Honeybee Evolution, Single-Cell Histones

In Genome Research this week: influence of microbes on transfer RNA patterns, evolutionary relationships of honeybees, and more.